Literature DB >> 18291615

[Chronic viral hepatitis and kidney failure].

Nabil Ben Chaabane1, Hichem Loghmari, Wissem Melki, Olfa Hellara, Leila Safer, Fethia Bdioui, Hammouda Saffar.   

Abstract

Chronic viral hepatitis remains a major problem among patients with chronic renal failure. Hepatitis B and C viruses are frequent among dialysis patients and after renal transplantation and may significantly diminish the survival of both the patient and the graft. Hepatitis B and C viral infection in these patients is often characterized by normal transaminase levels despite viremia and progressive liver lesions. Liver biopsy remains essential for assessing the extent of liver disease. Cirrhosis is a contraindication to transplantation of only a kidney, because of elevated morbidity and mortality. A combined as liver-kidney transplantation may be considered. The best treatment of hepatitis infections is preventive: vaccination against the hepatitis B virus and attentive hygiene, especially to prevent nosocomial transmission. Among patients not awaiting transplant, antiviral treatment should be reserved for patients with active or even fibrotic liver disease. For hemodialysis patients awaiting kidney transplant: Alpha interferon is ineffective and poorly tolerated by dialysis patients. Lamivudine is effective and well tolerated, but its long-term efficacy and its optimal effective dose in dialysis patients remain unknown.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18291615     DOI: 10.1016/j.lpm.2007.10.013

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  3 in total

1.  Immunogenicity of Four Doses of Double-Strength Intramuscular Hepatitis B.

Authors:  Seyed Ali Asghar Fakhrmousavi; Azar Hadadi; Seyed Hamed Hosseini; Maryam Rahbar; Reza Hamidian; Amitis Ramezani; Gholamreza Pourmand; Effat Razeghi
Journal:  Iran J Pathol       Date:  2016

2.  Chronic hepatitis B virus infection and total and cause-specific mortality: a prospective cohort study of 0.5 million people.

Authors:  Jiahui Si; Canqing Yu; Yu Guo; Zheng Bian; Ruogu Meng; Ling Yang; Yiping Chen; Jianrong Jin; Jingchao Liu; Ziyan Guo; Junshi Chen; Zhengming Chen; Jun Lv; Liming Li
Journal:  BMJ Open       Date:  2019-04-09       Impact factor: 2.692

3.  Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults.

Authors:  Jiahui Si; Canqing Yu; Yu Guo; Zheng Bian; Chenxi Qin; Ling Yang; Yiping Chen; Li Yin; Hui Li; Jian Lan; Junshi Chen; Zhengming Chen; Jun Lv; Liming Li
Journal:  BMC Med       Date:  2018-06-18       Impact factor: 8.775

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.